References
- . Michelson D, Faries D, Wernicke J, . Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83, 1–9
- . Wietecha LA, Williams DW, Herbert M, Melmed RD, Greenbaum M, Schuh K. Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(6):719–730
- . Michelson D, Adler L, Spencer T, . Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112–120
- . Strattera [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014
- . Data on file, Lilly Research Laboratories, STR20081007a
- . IMS Health, Processing and Data Delivery System–National Disease and Therapeutic Index; Strattera weighted average daily dose over time report, January 2006–December 2013
- . Alatorre C, Kabul S, Montejano L, Kelsey D. Real world dosing patterns of atomoxetine in adults with attention-deficit/hyperactivity disorder. Abstract. World Congress of Psychiatry, September 14–18, 2014. Madrid, Spain
- . Rappley MD. Attention deficit-hyperactivity disorder. N Engl J Med. 2005;352(2):165–173
- . Market Strategies International; Strattera marketplace tracker W2. 2014 report
- . Wietecha LA, Ruff DD, Allen AJ, Greenhill LL, Newcorn JH. Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies: a meta-analysis of company-sponsored studies. J Clin Psychiatry. 2013;74(12):1217–1223
- . Block SL, Kelsey D, Coury D, . Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. Clin Pediatr (Phila). 2009;48(7):723–733
- . Adler LA, Spencer T, Brown TE, . Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2009;29(1):44–50